A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC)
Publication Date
2025
Content Type
Article
PubMed ID:
Citation
BMC Cancer (2025) 25(1):1408
2025
Article
BMC Cancer (2025) 25(1):1408